Syndax Pharmaceuticals Inc financial data

Symbol
SNDX on Nasdaq
Industry
Pharmaceutical Preparations
Location
35 Gatehouse Drive, Building D, Floor 3, Waltham, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.02 K % -36.4%
Debt-to-equity 10 % +33.9%
Return On Equity -53.3 % -39.4%
Return On Assets -48.5 % -36.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 85 M shares +23.5%
Common Stock, Shares, Outstanding 85 M shares +24.1%
Entity Public Float 1.08 B USD +30.1%
Common Stock, Value, Issued 8 K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 85.2 M shares +22.7%
Weighted Average Number of Shares Outstanding, Diluted 85.2 M shares +22.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 185 M USD +51.4%
General and Administrative Expense 23 M USD +92.5%
Operating Income (Loss) -263 M USD -63.7%
Nonoperating Income (Expense) 22.8 M USD +200%
Net Income (Loss) Attributable to Parent -241 M USD -57%
Earnings Per Share, Basic -3.24 USD/shares -33.9%
Earnings Per Share, Diluted -3.24 USD/shares -33.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 115 M USD +99.3%
Other Assets, Current 6.07 M USD
Assets, Current 454 M USD +2.81%
Property, Plant and Equipment, Net 5 K USD -70.6%
Operating Lease, Right-of-Use Asset 1.24 M USD +33.8%
Other Assets, Noncurrent 248 K USD -64.2%
Assets 543 M USD +18.1%
Accounts Payable, Current 8.81 M USD +9.33%
Employee-related Liabilities, Current 4.57 M USD +49.6%
Liabilities, Current 50.8 M USD +114%
Operating Lease, Liability, Noncurrent 327 K USD -44.4%
Liabilities 51.1 M USD +110%
Retained Earnings (Accumulated Deficit) -975 M USD -32.8%
Stockholders' Equity Attributable to Parent 492 M USD +12.9%
Liabilities and Equity 543 M USD +18.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -83.5 M USD -113%
Net Cash Provided by (Used in) Financing Activities 2.17 M USD -12.4%
Net Cash Provided by (Used in) Investing Activities -99.4 M USD -599%
Common Stock, Shares Authorized 200 M shares +100%
Common Stock, Shares, Issued 85 M shares +24.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -181 M USD -974%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 206 M USD +54.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 206 M USD +54.8%
Operating Lease, Liability 1.61 M USD +41.1%
Depreciation 12 M USD -63.6%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -241 M USD -57.6%
Lessee, Operating Lease, Liability, to be Paid 1.8 M USD +33.4%
Property, Plant and Equipment, Gross 419 K USD 0%
Operating Lease, Liability, Current 1.04 M USD +130%
Lessee, Operating Lease, Liability, to be Paid, Year Two 606 K USD +3.59%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.2 M USD +111%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 189 K USD -9.14%
Deferred Tax Assets, Operating Loss Carryforwards 32.7 M USD +38.1%
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 143 K USD 0%
Operating Lease, Payments 924 K USD +63%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 33.6 M USD +79%
Interest Expense 223 K USD -91.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%